As the second decade of the 21st century draws to a close, we can take stock and potentially congratulate ourselves on the remarkable progress in the treatment and care of multiple sclerosis (MS). Improvements in the diagnosis of MS, proliferation of treatment options for relapsing forms of MS, and some, albeit modestly useful, treatments for the progressive forms of the disease, alongside a robust research and patient organization community, are all cause for measured celebration. In this issue, Walton et al.¹ remind us, however, that MS continues to be a growing global problem with variable access to treatment and that we need to calibrate our plaudits.

中文翻译：

---

MS 2020图集：通报全球政策变化

随着21世纪第二个十年的临近，我们可以总结一下，并有可能对多发性硬化症（MS）的治疗和护理取得显着进展表示祝贺。多发性硬化症的诊断改善，复发性多发性硬化症的治疗选择的泛滥以及一些渐进型疾病的治疗，尽管有一定程度的用处，但有力的研究和患者组织界，这些都是值得庆祝的原因。在这个问题上，沃尔顿等。¹提醒我们，MS仍然是一个日益严重的全球性问题，获取治疗的机会不断变化，我们需要校准自己的能力。